206 related articles for article (PubMed ID: 25533943)
1. Lung cancer in 2014: optimizing lung cancer treatment approaches.
Rosell R; Karachaliou N
Nat Rev Clin Oncol; 2015 Feb; 12(2):75-6. PubMed ID: 25533943
[TBL] [Abstract][Full Text] [Related]
2. The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer.
Ernani V; Steuer CE; Jahanzeb M
Annu Rev Med; 2017 Jan; 68():153-168. PubMed ID: 27618751
[TBL] [Abstract][Full Text] [Related]
3. [Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes].
Besse B
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S93-5. PubMed ID: 26118884
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
[TBL] [Abstract][Full Text] [Related]
5. [Molecular targeted therapies and cytotoxics: Friends or foes?].
Vignot S; Zalcman G
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S91-2. PubMed ID: 26118883
[No Abstract] [Full Text] [Related]
6. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Girard N
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
[TBL] [Abstract][Full Text] [Related]
7. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy.
Kaira K; Yamamoto N; Kenmotsu H; Murakami H; Ono A; Naito T; Endo M; Takahashi T
Respir Investig; 2014 Mar; 52(2):121-8. PubMed ID: 24636268
[TBL] [Abstract][Full Text] [Related]
9. Refining the treatment of NSCLC according to histological and molecular subtypes.
Thomas A; Liu SV; Subramaniam DS; Giaccone G
Nat Rev Clin Oncol; 2015 Sep; 12(9):511-26. PubMed ID: 25963091
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of (18)F-FDG PET-CT in evaluation of the therapeutic efficacy of chemotherapy for lung cancer].
Jia P; Guo WH; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):235-6. PubMed ID: 19615270
[No Abstract] [Full Text] [Related]
11. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
Reckamp KL; Koczywas M; Cristea MC; Dowell JE; Wang HJ; Gardner BK; Milne GL; Figlin RA; Fishbein MC; Elashoff RM; Dubinett SM
Cancer; 2015 Sep; 121(18):3298-306. PubMed ID: 26033830
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
13. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Felip E; Rojo F; Reck M; Heller A; Klughammer B; Sala G; Cedres S; Peralta S; Maacke H; Foernzler D; Parera M; Möcks J; Saura C; Gatzemeier U; Baselga J
Clin Cancer Res; 2008 Jun; 14(12):3867-74. PubMed ID: 18559607
[TBL] [Abstract][Full Text] [Related]
14. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.
Cappuzzo F; Bemis L; Varella-Garcia M
N Engl J Med; 2006 Jun; 354(24):2619-21. PubMed ID: 16775247
[No Abstract] [Full Text] [Related]
15. O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):6. PubMed ID: 24852396
[No Abstract] [Full Text] [Related]
16. MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):13. PubMed ID: 24852397
[No Abstract] [Full Text] [Related]
17. The cellular origins of drug resistance in cancer.
Oxnard GR
Nat Med; 2016 Mar; 22(3):232-4. PubMed ID: 26937615
[No Abstract] [Full Text] [Related]
18. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Weber B; Winterdahl M; Memon A; Sorensen BS; Keiding S; Sorensen L; Nexo E; Meldgaard P
J Thorac Oncol; 2011 Jul; 6(7):1287-9. PubMed ID: 21847041
[TBL] [Abstract][Full Text] [Related]
19. New agents in advanced non-small-cell lung cancer treatment.
Ricciardi S; de Marinis F
Oncology; 2009; 77 Suppl 1():103-12. PubMed ID: 20130438
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib in non-small cell lung cancer treatment: current status and future development.
Gridelli C; Bareschino MA; Schettino C; Rossi A; Maione P; Ciardiello F
Oncologist; 2007 Jul; 12(7):840-9. PubMed ID: 17673615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
